ZERANOL EXPLANATION Zeranol was considered at the twenty-sixth meeting of the Joint FAO/WHO Expert Committee on Food Additives (Annex 1, reference 59), but it could not be evaluated at that time because the necessary documentation on residue levels, good animal husbandry in relation to the use of the agent, and details of methods of analysis were not available. At the twenty-seventh meeting (Annex 1, reference 62), the Committee provisionally accepted the use of zeranol as an anabolic agent for the production of meat for human consumption in accordance with good animal husbandry practice, and requested submission of the results of (1) a study known to be in progress to establish a no-effect level for hormonal activity in non-human primates and (2) adequate carcinogenicity studies in two rodent species. This monograph contains the data previously considered by the Committee, as well as data that have been submitted recently. BIOLOGICAL DATA Toxicological studies Special studies on carcinogenicity Mice Four groups of 50 male and 50 female CDI mice each were maintained on diets containing 0, 0.15, 1.5, or 15 ppm zeranol for 104 weeks. Another group of 50 male and 50 female CDI mice, which served as a positive control, were maintained on a test diet containing 2.5 ppm estradiol-17ß. Haematology studies on 10 males and 10 females/group were carried out at weeks 26, 52, and 78 and on all surviving animals at week 104. At week 104 of the study all surviving mice were killed and autopsied. Full histopathological examinations were performed on all control, highest-dose zeranol, and estradiol-17ß test animals, as well as on all animals dying during the course of the study. Partial histopathological examinations (adrenals, kidneys, liver, lungs, mammary gland, uterus, vagina, cervix, prostate, seminal vesicles, testes, pituitary, skin, and all masses seen directly) were performed on all other animals. Mortality in the animals treated with zeranol was slightly higher than in controls. However, mortality was markedly increased in the animals fed estradiol-17ß, particularly in females. Male mice treated with zeranol showed a slight decrease in body weight compared to control mice during the first 52 weeks of the study, but the effect was not apparent during the second 52-week period. In contrast, males treated with estradiol-17ß showed a significant decrease in body weight throughout the course of the study. Females on the test diets showed similar weight gains to the controls. The levels of food consumption of male and female mice on diets containing zeranol and of males receiving estradiol-17ß were similar to controls. Females receiving estradiol-17ß showed increased food consumption (from week 80) compared to the control animals. During the course of the study, there were minor changes in haematological parameters in the mice treated with zeranol. Dosing with estradiol-17ß resulted in a reduction in haemoglobin levels and red blood cell count in males, and changes in the differential white blood cell patterns in females. At autopsy, a few significant changes were observed in the mice fed 15 ppm zeranol, namely pituitary enlargement and dilation of the seminal vesicles in males. In female mice there was an increased incidence of alopecia. The incidences of these changes were greatly increased in mice in the positive control group. Histopathological examination of the highest-dose zeranol- treated mice showed brown degeneration in the adrenals in both sexes and conversion of the submaxillary salivary glands to the female type, trabeculation in the sterum, and dilation of the seminal vesicles in males. These estrogenic effects were very mild compared to those in mice fed estradiol-17ß. In the 0.15 ppm, but not the 1.5 ppm, group the incidences of ovaries with corpora lutea present and no secondary follicles (females) and dilatation of the seminal vesicles (males) were significantly decreased compared with controls. However, these effects were not considered to be true hormonal effects, because (1) the effect on the ovaries was not dose related and (2) the lower incidence of dilatation of the seminal vesicles was more common in older animals, and the lower incidence in treated animals probably was related to the longer average survival time of the controls. Other significant effects observed in the 15 ppm zeranol group included an increase in mucous cervical and vaginal epithelium (20/46 compared to 10/48 in controls; 0/47 in the positive control group) and subcapsular hyperplasia of the adrenals in males (30/49 compared to 16/50 in controls). The only tumourogenic effect of zeranol noted in this study was in the pituitary gland of males in the highest-dose group. The incidences of anterior lobe adenomas and hyperplasia plus tumours in the anterior lobe noted in this study are summarized in Table 1. Table 1. Incidences of hyperplasia and rumours of the pituitary gland in male mice Negative Zeranol (ppm in the diet) Positive Finding control 0.15 1.5 15 control Anterior lobe 1 0 0 8 28 adenoma Hyperplasia + 1 2 2 12 33 rumours in anterior lobe These tumours rarely occur spontaneously in mice. However, neoplasia of the pituitary gland has been associated with the administration of estrogen to certain strains of mice (Gardner, 1941), and it is considered to be associated with hormonal imbalance resulting from the administration of estrogenic hormones (Gardner, 1941, 1948). In the estradiol-17ß group, the estrogenic effects were more marked than those observed in mice treated with zeranol. These effects included brown degeneration in the adrenals, increased trabeculation in the sternum, conversion of male submaxilliary salivary glands to the female type, shrinkage of seminal vesicles, scarcity of secondary follicles and corpora lutea in the ovaries, uterine inflammation, endometriosis and hyalinization, cervical adenosis, vaginal epithelial keratinization, and mammary gland development. Tumourgenic effects in the positive controls included anterior lobe tumours of the pituitary gland and testicular interstitial cell tumours in males and mammary gland carcinomas with metastasizing adenocarcinomas in females (Everett, et al., 1987a). Rats Four groups of 50 male and 50 female Sprague-Dawley rats each were maintained on diets containing 0 (negative control), 0.25, 2.5, or 25 ppm zeranol for 104 weeks. Two other groups of 25 male and 25 female rats each, which served as positive dietary controls, were maintained on diets containing either 2.5 ppm estradiol-17ß throughout the study or 25 ppm estradiol-17ß for 8 weeks, which was reduced to 2.5 ppm for the rest of the experiment (toxicity was observed at 25 ppm). In another group of 25 females, which served as an implant positive control group, each animal was implanted s.c. with approximately 15 mg estradiol-17ß at the commencement of the study. Haematology studies on 10 males and 10 females per group were carried out at weeks 26, 52, and 78 of the study and on all surviving rats at 104 weeks. Haematology, clinical chemistry analyses, and urinalyses were carried out on 15 males and 15 females per group (where available) at week 103 of the study. At week 104, all surviving animals were killed and autopsied. Full histopathological examinations were performed on all control, highest-dose zeranol, and estradiol-17ß test animals. Partial histopathological examinations (adrenals, cervix, ovaries, pituitary, prostate, seminal vesicles, testes, skin, kidneys, liver, lungs, mammary gland, and masses) were carried out on all other test animals. Animals dying during the course of the study were autopsied and complete histological examinations were performed on them. Male rats in the highest-dose zeranol group showed a slight decrease in weight gain compared to negative controls during the first 52 weeks of the study, but weight gains were similar to controls during the remainder of the study. A slight decrease in body weight was observed in males in the 0.25 ppm group and in females in the 0.25 and 2.5 ppm groups. Females in the highest-dose group showed similar weight gains to controls, except during the first 90 days of the study, when a reduction in body weight was observed. In contrast, rats receiving estradiol-17ß showed a marked reduction in body weight, the greatest depression being noted in females implanted with estradiol-17ß. Levels of food consumption in the negative control and groups fed zeranol were similar. There was some reduction in food intake in rats in the positive control groups. Haematological studies showed that female rats in the 0.25 ppm zeranol group had increases in red blood cell parameters (haemaglobin level and red blood cell count) and white blood cell counts compared to controls. Animals in all other zeranol test groups had results similar to negative controls. Female rats in the positive dietary control groups showed elevated white blood cell counts, whereas those implanted with estradiol-17ß showed decreases in red blood cell parameters and increased neutrophil counts. There were no significant inter-group differences in clinical chemistry or urinalysis results. Survival of test animals was similar in the negative control and zeranol test groups. In the positive dietary control groups, survival was lower than in the zeranol groups, but most deaths occurred after 80 weeks of treatment. In the group implanted with estradiol-17ß, deaths occurred after 20 weeks, and there were no survivors at week 44 of the study. No common causes of death were noted in the treated animals receiving zeranol, although those receiving estradiol-17ß showed a higher incidence of enlarged pituitaries than did controls. At autopsy, organ weight analyses of rats fed zeranol showed no significant differences between male rats and their respective controls. There was an apparent increase in uterus weight in females in the highest-dose group, but because of the large variation in ovary weights in this group, this was not statistically significant. Male rats receiving dietary estradiol-17ß had significantly-decreased kidney weights, and females had reduced absolute ovary weights compared to controls. Histological examination of the tissues of the zeranol-treated animals showed no compound-related increases in neoplasms. Non-neoplastic findings in female rats included an increase in dilatation of the uterus in the highest-dose group, as well as an increase in stratified squamous epithelial cells of the cervix in the 2.5 and 25 ppm groups. There was an increase in mammary hyperplasia in the 2.5 ppm group, but this was not statistically significant when an age-adjustment analysis was carried out. Kidney tubular epithelial haemosiderosis occurred more frequently in the 0.25 ppm test group than in controls, but this was not considered to be a compound-related effect. All females treated with estradiol-17ß showed marked estrogenic effects, with significant changes in the ovaries, uterus (including squamous metaplasia and epithelial dysplasia), vagina and cervix, and mammary glands. Effects were also reported in the spleen, sternum, stomach, kidney, and lungs. In males treated with estradiol-17ß, effects were observed in the liver, pancreas, mammary gland, heart, testes, kidneys, and spleen. Histopathological changes in animals treated with estradiol-17ß implants were more severe than those in animals receiving estradiol-17ß in the diet. There was also a marked increase in pituitary adenomas (type 3) in test animals in the implant group compared with controls (Everett, et al., 1987b). Special study on estrogenic potency The uterotropic response in sexually immature rats was used to compare the estrogenic potency of zeranol and its metabolites zearalanone (the 7-keto oxidation derivative) and taleranol (7-ß-hydroxy epimer of zeranol) with estradiol-17ß. Administration of the test compound by the oral route showed the estrogenic potency of zeranol, zearalanone, and taleranol to be 1/150, 1/400, and 1/350, respectively, that of estradiol-17ß. By the s.c. route zeranol was 1/500 less estrogenic than estradiol-17ß (Everett et al., 1987c). Special studies on no-hormonal effect levels Monkeys Eighteen female cynomolgus monkeys were bilaterally ovariectomized. After an 11-week stabilization period, the animals were assigned to 3 groups. The test groups were then dosed orally with zeranol in 0.2% carboxymethylcellulose in a flavoured beverage at dose levels equivalent to 0.05, 0.5, or 5 mg/kg b.w./day for 13 weeks. A control group was not used. Routine clinical chemistry, haematology, and urinalysis determinations were made one month prior to dosing, and at 1 and 3 months during the test period. Serum levels of insulin and thyroid stimulating hormone (TSH) were determined once prior to dosing, and at 1 and 3 months during the dosing period. FSH was determined on a weekly basis during the study through 4 weeks post-dosing. Clinical chemistry, haematology, and urinalysis parameters were within the normal ranges. No compound-related effects were observed on serum levels of insulin or TSH. FSH values during the 24 hours after the first daily dose of zeranol showed some variation, but no biphasic response was observed. FSH values measured during the course of the study showed variations, but no consistent depression was observed. Baseline measurements and measurements of maturation index of vaginal epithelial cells during the course of the study indicated an estrogenic effect in animals receiving 0.5 and 5 mg/kg b.w./day zeranol. The effect was not apparent at 0.05 mg/kg b.w./day (Singh et al., 1984a; CIC, 1985). Three groups of 6 mature male cynomolgus monkeys each were dosed daily with zeranol at levels equivalent to 0.05, 0.5, or 5 mg/kg b.w./day for a period of 13 weeks. Routine clinical chemistry, haematology, and urinalysis determinations were made in each of the animals twice prior to dosing, then after 1 and 3 months of dosing. Serum levels of insulin, FSH, and testosterone were also measured. At the end of the dosing phase, testicular biopsies were taken and examined microscopically. Body-weight gain was normal during the test period. Clinical chemistry, haematology, and urinalysis parameters were within normal limits. Serum levels of insulin, TSH, and FSH showed no compound- related changes. Testosterone levels were highly variable in individual animals, but they showed no compound-related effects. Examination of testicular biopsies showed no effects on the spermatogonia, the primary and secondary spermatocytes, or the sperm. The Leydig cells were normal (Singh et al., 1984b). Five groups of 6 sexually mature adult intact female cynamologus monkeys each were used for this study. Three groups were administered zeranol orally on a daily basis for 3 menstrual cycles at dose levels equivalent to 0.05, 0.5, or 5 mg/kg b.w./day. One group was dosed with the vehicle (0.2% carboxymethycellulose in a fruit flavoured drink) and the other with estradiol-17ß at a dose level equivalent to 0.01 mg/kg b.w./day. Haematology, clinical chemistry, and urinalysis determinations were made prior to dosing, during the dosing phase, and during a withdrawal period. Serum levels of insulin, TSH, FSH, estradiol-17ß, and progesterone were measured during the course of the study (every third of the menstrual cycle). Vaginal cornification (maturation index) and daily observations were made for changes in sex skin coloration or swelling. No treatment-related effects on body weight were observed. Sex skin changes during the cycles of dosing and withdrawal showed no compound-related effects in animals treated with zeranol or estradiol-17ß. None of the treatments had a significant effect on clinical chemistry or haematology parameters or on serum levels of insulin or TSH. There were no compound-related effects on serum levels or cyclic behaviour of FSH, estradiol, or progesterone in any of the test groups. There was no significant change in the type of vaginal epithelial cells during the dosing phase of the study (Singh et al., 1984c; Singh & Griffin, 1984). Three groups of 8 mature female rhesus monkeys each were dosed daily with zeranol at levels equivalent to 0.5, 5, or 50 mg/kg b.w./day for three menstrual cycles, or 111 days, after a pretreatment control cycle. A control group of 6 monkeys received the vehicle (orange juice) used to suspend the zeranol. Daily blood samples were taken from each animal during the last pretreatment control cycle, every-other-day during the first two treatment cycles, and daily during the treatment cycle. Serum concentrations of estradiol, progesterone, LH and FSH were determined by radioimmunoassay. The average menstrual cycle showed no significant compound- related effects in the 0.5 or 5 mg/kg b.w./day group. By contrast, the menstrual cycle in the high-dose group was completely inhibited during the first 60 days of treatment, and markedly inhibited during the third cycle. Ovulation rates were similar in the control, low-dose, and mid-dose groups, but markedly inhibited in the high-dose group. No differences were observed in the quantitative pattern of estradiol secretion in the control and mid-dose groups; however, the pattern was altered in the high-dose group, where estradiol levels were significantly reduced. LH and FSH levels and patterns of secretion were similar to those observed in the pretreatment cycle in the control, low-dose, and mid-dose groups, but levels were high in the high-dose group, and the pattern of secretion was different than in the other groups (Hess, 1986). Special studies on mutagenicity The available mutagenicity data on zeranol and its metabolites, zearalanone and taleranol, are summarized in Tables 2, 3, and 4. Special studies on reproduction Rats Groups of 10 male and 10 female Sprague-Dawley rats, weighing approximately 200 g each that were 7 weeks of age at the beginning of the study, were maintained on diets containing 0, 0.25, 1.77, 12.5, or 25 ppm zeranol commencing 4 weeks prior to mating and continuing until termination of the study. The offspring (F1 generation) were maintained on the test diets for 3 to 4 weeks after weaning. F0 males and females were killed and necropsied after their respective functions were completed. The F1-generation animals were killed and necropsied at approximately 6 weeks of age. The F0 males showed a reduction in body weight compared to controls at all dose levels (19% in the high-dose group). Food consumption of males fed zeranol was also reduced. Although F0 females fed zeranol showed only a slight reduction in food intake compared to controls, those in the 12.5 and 25 ppm groups showed significant reductions in body weight (21% in the high-dose group). Indices of fertility and general reproduction were evaluated using the fertility index, gestation index, live birth index, viability index (days 0 - 4), and lactation index (days 4 - 21). There were no significant dose-related effects. Male and female pups in the high-dose group showed a significant reduction in body-weight gain during the lactation period, and this was maintained during the post-weaning period. Decreased weight gain was also observed in the 12.5 ppm group, but not in the lower-dose groups. At autopsy, absolute and relative organ weight analyses of the F0-generation animals showed decreased liver weight in all test groups. All males fed zeranol showed reduced absolute and relative seminal vesicle weights, and females had reduced absolute and relative ovary weights. Gross necropsy of the animals from both generations did not show any compound-related effects (Everett & Perry, 1984). Table 2. Results of mutagenicity assays on zeranol Test system Test object Concentration Results Reference Ames test1 S. typhimurium 1 - 500 µg/plate Negative Bartholomew & Ryan, TA98, TA100, 1980 TA1538 Ames test2 S. typhimurium 1 - 10000 µg/ Negative Jagannath, 1982a TA100 plate Forward Mouse lymphoma 25 - 600 µg/ml Negative Cifone, 1982 mutation L5178Y TK+/- assay1 -3.7.2C cells Bone marrow CD-1 mice 0.5, 1.5, 5 g/kg Negative Cimino, 1982 cytogenic assay Hepatocyte Adult male 1.3 × 10-3 to Negative Williams, 1983 primary F344 rats 1.3 × 10-5 mg/ml culture DNA repair assay DNA binding Rat hepatocyte Not available Negative Williams, 1984 assay primary cell culture Rec-assay B. subtilis Not available Positive Scheutwinkel et al., H17, M45 1986 SOS-chromo E. coli Not available Negative Scheutwinkel et al., test2 PQ37 1986 V79/SCE Chinese hamster Not available Negative Scheutwinkel et al., test2 V79 cells 1986 1 With rat liver S-9 fraction. 2 Both with and without rat liver S-9 fraction. Table 3. Results of mutagenicity assays on zearalanone1 Test system Test object Concentration Results Reference Ames test2 S. typhimurium 50, 500, 1000 µg/ Negative Ingerowski et al., TA98, TA100, plate 1981 TA1535, TA1537 TA1538 Ames test3 S. typhimurium 1.0 - 10000 µg/ Negative Jagannath, 1982b TA98, TA100, plate TA1535, TA1537 TA1538 Forward Mouse lymphoma 3.13 - 300 µg/ml Negative Cifone, 1983 mutation L5178Y TK +/- assay cells Bone marrow CD-1 mice 0.5, 1.67, Negative Cimino, 1983 cytogenic 5 g/kg assay Hepatocyte Adult male 5 × 10-10 to Negative Williams, 1985a primary F344 rats 5 × 10-4 mg/ml culture DNA repair assay 1 7-keto oxidation derivative of zeranol. 2 With rat liver S-9 fraction. 3 Both with and without rat liver S-9 fraction. Special studies on teratogenicity Mice Pregnant CDI-1 mice were injected s.c. with log doses of zeranol ranging between 10 and 10000 ug/kg b.w./day on days 6 - 10 of gestation. Half of the mice were allowed to deliver, and the remaining half were delivered by caesarian section. At doses of 1000 and above the number of litters decreased from 81% in the controls to 35% in the treated animals. A decrease in the average weight of the pups and an increased number of stillborn litters were observed. Limited macroscopic examination showed increased medullary trabeculae in the bones (Davies et al., 1977). Rats Groups of 4 female pregnant rats received zeranol orally in single doses of 4 mg on days 1, 2, 3, 4, and 5 of gestation, 1 mg/day during days 1 - 4 of gestation, or a single dose of 8 mg on day 6 of gestation. The rats were killed on day 9 of gestation. Zeranol appeared to inhibit implantation up to day 4 of administration. In experiments in which implantation occurred, the fetuses had begun to resorb by day 9 (IMC, 1980a). Table 4. Results of mutagenicity assays on taleranol1 Test system Test object Concentration Results Reference Ames test2 S. typhimurium 1 - 500 µg/plate Negative Bartholomew & Ryan, TA98, TA100 1980 TA 1548 Ames test3 S. typhimurium 1 - 5000 µg/plate Negative Jagannath, 1983 TA100 Forward Mouse lymphoma 20 - 160 µg/ml Borderline Cifone, 1985 mutation L5178Y TK+/- assay2 -3.7.2C cells Bone marrow ICR mice 8.5 - 85 mg/ml Negative Ivett, 1985a cytogenic assay Hepatocyte Adult male 2 × 10-5 to Negative Williams, 1985b primary F344 rats 2 × 10-1 mg/ml culture DNA repair assay Chromosomal Chinese 12.5 - 250 µg/ml Positive Ivett, 1985b aberration hamster ovary (- act.) frequency cells Negative assay3 (+ act.) Dominant H/a (ICR)BR 0.5, 1.5, 5.0 Negative Brusick & Myhr, lethal assay mice g/kg b.w./day 1986 1 7ß-hydroxy epimer of zeranol. 2 With rat liver S-9 fraction. 3 Both with and without rat liver S-9 fraction. A three-generation study in rats was performed in which males weighing 69 - 113 g each and females weighing 65 - 109 g each were fed zeranol in the diet at levels of 0, 0.01, 0.10, or 0.20 ppm for each successive generation, each comprising three consecutive litters. Animals in each generation received zeranol in the diet for 70 days prior to mating, they were removed from the diet from day of delivery of the dams throughout lactation until weaning, and then they were reinstated at the same levels as at the start of the study. Pups from the Fb litters were used for the reproduction of the subsequent generation; the pups from the Fc litters were used for the teratogenicity study. While there were some differences in the litter data for the three consecutive generations which appeared to be significant, there was no trend or dose-response relationship. No adverse effects were observed which could be attributed to treatment with zeranol (Wazeter & Goldenthal, 1976). Zeranol, administered orally at doses of 0.312, 1.25, or 5.0 mg/kg b.w./day to male rats for 60 days prior to mating with untreated females, induced delayed insemination upon cohabitation and delayed initiation of conception in the females (Williams, 1982). Zeranol, administered orally at doses of 0.312, 1.25, or 5.0 mg/kg b.w./day to female rats for 60 days prior to mating with untreated males, caused a decrease in the litter size, an increase in stillbirths, and a decrease in neonate survival (Williams, 1982). Pregnant female rats were administered orally 2 or 6 mg/kg b.w./day zeranol from days 6 - 15 of gestation. At laparotomy on day 20 of gestation, reduced numbers of live fetuses and increased numbers of resorptions were noted (Williams, 1982). Rabbits Zeranol was administered orally at doses of 1 or 5 mg/kg b.w./day to pregnant does on days 6 - 18 of gestation. Fetuses were removed by laparotomy on day 28. No abnormalities were noted (Williams, 1982). Acute toxicity Species Sex Route LD50 Reference (g/kg b.w.) Mouse ? oral > 40 IMC, 1980b F i.p. 4.4 IMC, 1980b Rat ? oral > 40 IMC, 1980b F i.p. 9-11 IMC, 1980b Groups of 25 rats/sex/dose received by oral gavage 0 or 200 mg/kg b.w. zeranol, and they were sacrificed 24 hours after dosing. There was a decrease in blood glucose levels in all treated rats, and an increase in total cholesterol in the males and a decrease in the females. There was a decrease in the weight of the epididymis of the males, and an increase in uterine weight in the females (Albany Medical Collage, 1980). Short-term studies Mice Groups of 20 CD-1 mice equally divided by sex were maintained on diets containing 0, 1, 5, 25, 50, or 100 ppm zeranol for 8 weeks. No deaths or clinical effects were observed during the course of the study. There were no significant differences in body weights, food consumption, or water consumption between test and control groups. At autopsy, no compound-related gross lesions were observed. No compound-related differences were observed in absolute or relative organ weights between test and control groups of the liver in males and females or of the testes in males. However, changes were observed in the absolute and relative weights of the ovaries (decreased) at dose levels of 25, 50, and 100 ppm zeranol and of the uterus (increased) at 100 ppm zeranol in females (Perry & Everett, 1984). Rats Groups of 40 Sprague-Dawley rats equally divided by sex were maintained on diets containing the equivalent of 0, 0.02, 0.18, 1.2, or 8.8 mg/kg b.w./day zeranol for a period of 13 weeks. Body weights and food consumption were determined weekly. Haematological, clinical chemistry, and urinalysis studies were carried out at weeks 5 and 13. Ophthalmoscopy was carried out at week 10. At termination of the study, gross observations and organ weight determinations were made on all animals, and histopathological examinations were performed on the principal organs and tissues from 10 animals of each sex in the high-dose and control groups. Six deaths occurred during the course of the study, which did not appear to be compound-related. Only minor decreases in food consumption were observed in the test groups compared to the control. However, there was marked reduction in weight gain compared to controls in the high-dose group, particularly in males. No compound- related changes were observed in haematological, clinical chemistry, or urinalysis parameters. Organ-weight analysis showed a slight increase in relative liver weights in both males and females and in the kidneys of rats in the high-dose group. Histological examination showed an increased incidence of vacuolation in hepatocytes from both males and females in the high-doss group as well as fat accumulation in these cells. The kidneys of males in the high-dose group showed a significant increase in calcified casts. These effects were only marginal in the 1.2 mg/kg b.w./day group. No compound-related effects were observed at 0.18 mg zeranol/kg b.w./day (Everett et al., 1983). Twenty intact juvenile female rats were implanted s.c. with 12 mg pellets of zeranol and sacrificed after 150 days. Five control animals were used. Decreased growth, cysts in the ovaries, mammary glands, and other parts of the body, decreased ovarian and uterine weights, absence of corpora lutea, and marked squamous metaplasia of the uterine mucosa were noted (Huis in't Veld & Kroes, 1974). Groups of 30 - 35 rats/sex/group received by oral gavage 0 or 200 mg/kg b.w./day zeranol for 4 days. There were decreases in total cholesterol and blood glucose levels, decreases in weights of the testes, seminal vesicles, and epididmes of males, increases in weights of the adrenals of males, and increases in weights of the uterus and adrenals of females. Microscopically, the ovaries showed prominent corpora lutea, and the testicular tubules contained spermatogonia but no adult or mature spermatozoa. The lymphoid tissue contained a number of large multinucleated cells (Albany Medical College, 1980). Groups of 5 albino Manor Farm rats/sex/dose received by oral gavage 25, 50, 100, 200, or 400 mg/kg b.w./day zeranol 5 days/week for 6 weeks. A control group was not included. During the 4th week of the study, the 100 mg dose was increased to 800 mg/kg b.w./day and the 200 mg dose was increased to 1600 mg/kg b.w./day. Effects were observed in all treatment groups that included changes in external genitalia (reduction in the size of the testes in males and enlargement of the vulva in females). Irritability, flaccidity, alopecia, excessive micturition, and reduced growth rate were also noted. After microscopic examination, changes noted were spermatogenic arrest, atrophy of the prostate, seminal vesicles, and coagulating glands, absence of graafian follicles, endometrial hyperplasia, squamous metaplasia of the seminal vesicles, and calcified casts in the kidneys (IMC, 1980c). Three groups (number not given) of male and female Sprague-Dawley rats received s.c. 0, 2.25, or 9.0 mg/kg b.w./day zeranol for 14 days. The growth rate was reduced in the treated animals. There were decreases in the relative weights of the gonads, prostate, and thymus in males and of the gonads and thymus in females. Additionally, there were increases in the relative weights of the seminal vesicles and adrenals in males and of the uterus and adrenals in females. A significant reduction in the number of corpora lutea was also noted (IMC, 1980d). Groups of male and female rats received 0.25, 1.25, or 6.25 mg/kg b.w./day zeranol in the diet for 13 weeks. Slight growth suppression at the two highest doses was observed (Williams, 1982). Groups of male and female rats were administered 0.1, 0.8, or 6.4 mg/kg b.w./day zeranol for 26 weeks. Reduced food intake and body-weight gains, a tendency toward lower haemoglobin values in males, and mild hepatic changes, including irregularity in hepatic cell size, were noted in females at the highest dose (Williams, 1982). Dogs One dog/sex/dose received orally by capsule 25, 50, 100, 200, or 400 mg/kg b.w./day zeranol 5 days/week for 6 weeks. During the 4th week of treatment the 100 mg dose was increased to 800 mg/kg b.w./day and the 200 mg dose was increased to 1600 mg/kg b.w./day. No control animals were included. Beginning with the second week of treatment, all females showed swollen vulvae. All males showed a decrease in testicular size. At a dose of 100 mg/kg b.w./day and above, males and females showed slight to marked increases in leucocytes and relative decreases in lymphocytes. At 200/1600 mg/kg b.w/ day, there were slight decreases in haemaglobin and haematocrit values, and increases in erythrocyte sedimentation rates. Microscopically, mammary ductal proliferation was noted in both males and females, vulval swelling with cornification of vaginal epithelium and ovarian atrophy was observed in females, and atrophy of the seminiferous epithelium and prostate and hyperplasia or squamous metaplasia of the prostatic urethra were noted in males. At doses of 400 mg/kg b.w./day and above, there were increases in bone marrow cellularity and in the myeloid/erythrocyte ratio (Williams, 1982). Groups of male and female dogs received orally by capsule 0.25, 1.25, or 6.25 mg/kg b.w./day zeranol for 14 weeks. Following the thirty-first dose, the 0.25 mg dose was increased to 12.5 mg/kg b.w./day. There was a trend toward a reduction in the size of the male sex organs and an increase in uterine weight. Microscopically, there was an arrest in spermatogenesis, and prostatic epithelial atrophy was seen in one male at 12.5 mg (Williams, 1982). Groups of male and female dogs were fed diets containing 10, 100, or 1000 ppm zeranol for 29 weeks. At 1000 ppm, noted changes included weight loss in one male, rapid sedimentation rates, reduced haemoglobin, increased leucocytes, and reduced lymphocytes in 3 males. Microscopically, changes noted in the 1000 ppm group included testicular atrophy, squamous metaplasia of the prostate, endometrial hyperplasia, and ovarian atrophy. Hypercullularity of the bone marrow and slight squamous metaplasia of the bladder were also noted (Williams, 1982). Long-term studies Rats Groups of 25 - 35 male and female rats were fed 0, 0.1, 0.8, or 6.4 mg/kg b.w./day zeranol for one year. During the 36th week of the study the 0.1 mg/kg b.w./day dose level was increased to 20 mg/kg b.w./day. Body-weight gain was depressed in all the treated animals. The rats in the 0.1/20 mg/kg b.w./day group showed depressed haemoglobin, increased thrombocyte counts, increased prothrombin time, decreased absolute and relative weights of the prostate, ovary, and seminal vesicles, and increased absolute and relative weights of the uterus and pituitary. Hepatic cell glycogen depletion and irregularity in hepatic cell size were observed in male rats only. Nephron degenerative changes, slight to moderate atrophy of the ovary, seminal vesicles, and prostate, slight reduction in the number of mature spermatozoa, and instances of hypocellularity of the bone marrow were also noted in this group of animals. Marked degenerative changes were seen in the livers of the animals which died during the study (Williams, 1982). Groups of 25 Charles River CD rats/sex/dose were fed 0, 0.1, 0.8, or 6.4 mg/kg b.w./day zeranol for 104 - 105 weeks. During the 28th week of the study the 0.1 mg/kg b.w./day dose level was increased to 20 mg/kg b.w./day. Body-weight gain was depressed in all the treated animals in the 6.4 and 0.1/20 mg/kg b.w./day dose groups. Greater frequency of alopecia was observed in the two highest dose groups, and one rat in the 6.4 and 4 rats in the 0.1/20 mg/kg b.w./day dose groups developed cataracts during the last quarter of the study. Haemoglobin and haematocrit values were reduced at 0.1/20 mg/kg b.w./ day, which was more severe in females than in males. The animals in the 0.1/20 mg/kg b.w./day group had lower absolute weights of the seminal vesicles, testes, ovaries, and prostate. Macroscopically, the findings were those commonly noted in aging animals. Microscopically, changes were seen in the liver, ovaries, uterus, testes, prostate, and seminal vesicles of all the rats treated with zeranol. The changes in the liver included hepatic cell depletion, irregularity in hepatic cell size, parenchymal cell vacuolation, chronic inflammatory cell infiltrates, and occasional instances of nodular hyperplasia; in the ovaries, prostate, seminal vesicles, and testes, slight to moderate atrophy was noted; in the uterus the observed changes included endometritis, squamous metaplasia, and cystic hyperplasia of the endometrium (Woodard, 1968). Dogs Groups of male and female dogs were fed 0.025, 2.5, or 25 mg/kg b.w./day zeranol for one year. Slight testicular atrophy, moderate prostatic atrophy, and squamous metaplasia were observed at the middle dose. At the high dose, observed changes included increased thrombocytes, decreased lymphocytes, rapid sedimentation rates, elevated leucocyte counts, and marked cornification of the vaginal epithelial cells. At terminal sacrifice, treatment-related changes in the 25 mg/kg b.w./day group included marked atrophy of the gonads, squamous metaplasia and inflammatory changes in the prostate and uterus, squamous metaplasia of the urinary bladder epithelium, an apparent increase in the myeloid elements of the bone marrow, and endometrial hyperplasia (Williams, 1982). Groups of 4 beagle dogs/sex/dose were fed 0, 1, 100, or 1000 ppm zeranol in the diet for 104 weeks. Body weights of the male dogs in all treatment groups were slightly higher than those of the controls. Most of the observed changes were noted at the highest dose. Haematological changes included rapid sedimentation rates, high leucocyte counts, and reduced lymphocytes. Increased relative weights of the prostate and pituitary and decreased relative weights of the gonads in males, increased uterine relative weights in females, and increased relative weights of the liver, kidneys, adrenals, and thyroid of both males and females at the highest dose were noted. Macroscopically, observed changes included enlarged mammary glands, small testes, edematous prepuces, and enlarged vulvae, prostate, and uteri. Microscopically, marked atrophy of the gonads, especially the ovaries (which were reduced to cysts), squamous metaplasia and inflammatory changes in the uterus and prostate, and chronic inflammatory changes in the bladder were observed. Two males and one female in the 100 ppm group had varying degrees of myeloid hyperplasia and one male had marked atrophy of the bone marrow (Woodard, 1968). Groups of 16 female beagle dogs were administered orally by capsule 0, 15, or 38 mg/kg b.w./day zeranol in a cyclic manner (21 consecutive days of dosing followed by 7 days off the drug) for a period of seven years (91 cycles). Two high-dose and two low-dose dogs died during the third year, and 3 low-dose dogs died or were sacrificed in a moribund state during the fourth year of the study. Clinical signs of toxaemia and gross lesions associated with pyometritis were noted in these dogs. To prevent further deaths related to pyometritis all surviving dogs were hysterectomized at 3 - 3.5 years into the study. Prior to hysterectomy, an increased incidence of anorexia and lethargy were noted in the treated animals. Mean body weights were slightly lower than controls in the 15 mg/kg b.w./day group; they were significantly lower than controls in the high-dose group. Haematological changes included a slight but consistent reduction in absolute and relative adrenal weights in the animals in the low-dose group at the four year interim sacrifice. At terminal sacrifice, significant increases in mean and relative ovarian weights of the animals in both treated groups were noted. Zeranol had a relatively strong uterotropic effect and caused a sharp increase in the proliferation and cornification of the vaginal, cervical, and vulvar mucosa, cystic endometrial hyperplasia, endometriosis interna, and pyometritis (Hogan, 1981a). Monkeys Groups of 16 sexually mature female rhesus monkeys (Macaca mulatta) were administered orally by gavage 0, 15, or 75 mg/kg b.w./day zeranol in a cyclic manner (21 days of consecutive dosing and 7 days off the drug) for a period of 10 years (131 cycles). Control animals were administered the vehicle, which was a mixture of ethanol and methylcellulose. Interim sacrifice was performed at one year (2 animals) and at 2 and 4 years (4 animals each). Seven animals died during the first nine months of causes unrelated to treatment and were replaced to maintain the number of animals per group. Ophthalmological changes included bilateral hypopigmented foci in the macular and perimacular regions of the retina, grainy appearance of the macula, and diminution or loss of the macular reflex. Palpable mammary nodules and/or enlarged axillary lymph nodes were seen sporadically in some of the animals. Palpable uterine masses were observed in the high-dose animals at a markedly higher incidence than in the control and low-dose groups. Prolonged periods of amenorrhea were observed in the high-dose animals, which was followed, in later years of the study, by prolonged periods of vaginal bleeding. The treated monkeys gained less weight than the controls throughout the study; at termination the mean body weight of females at 15 mg/kg b.w./day was 15% lower, and that of females at 75 mg/kg b.w./day was 25% lower, than body weights of controls. During the first 1.5 years of the study there were transient reductions in mean haemaglobin concentrations and haematocrit and erythrocyte values in the treated animals as compared to the controls. Sporadic increases in the measured clotting time were noted throughout the study. No other haematological changes were noted. Sporadic increases in SGPT activity were noted at 15 mg/kg b.w./day, while consistently higher SGPT activities were observed at 75 mg/kg b.w./day. A similar pattern was observed with serum triglyceride and cholesterol concentrations. The animals in the high-dose group had consistently higher mean absolute and relative weights of the liver and uterus and lower mean absolute and relative ovarian weights than the controls. Similar observations, but to a lesser degree, were noted in the animals fed 15 mg/kg b.w./day zeranol. At terminal sacrifice, the mean relative weight of the pituitary and mean absolute and relative adrenal weights of the animals in the high-dose group were higher than those of the controls. No treatment-related macroscopic changes were noted at the 1- and 2-year interim sacrifices. At A years, there were dose-related increases in the incidence and degree of endometrial proliferation. At 10 years, treatment-related changes included enlarged uteri, thickened endometrium and myometrium, enlarged oviducts, and endometriosis externa. No treatment-related microscopic changes were noted at one year into the study. At two years, one benign adenoma was noted in one animal and a relative increase in mammary acinar tissue and duct development were noted at 75 mg/kg b.w./day zeranol. At 4 years, treatment-related changes in the high-dose group included endometrial hyperplasia with occasional cystically dilated glands (all 4 animals), absence of mature follicles and corpora lutea, superficial atrophy of the cervical epithelium with squamous metaplasia of the basilar portions of cervical glands, and increased lobular development and mild ductular epithelial proliferation. At 10 years, treatment-related changes were noted in most of the animals in the high-dose group that included hyalization of the subepithelial connective tissue in the vagina, squamous metaplasia of the basilar portions of the cervical glands, ovarian atrophy and absence of corpora lutea, and marked ductal and acinar hyperplasia of the mammary gland. Cystic endometrial hyperplasia, myometrial hypertrophy, and endometriosis externa were noted in all the animals at 75 mg/kg b.w./day zeranol and in three animals in the low-dose group. Leiomyomas of the uterus/cervix (fibroids) were present in 1/12, 2/7, and 2/14 animals in the control, low-, and high-dose groups, respectively (Hogan, 1981b). COMMENTS The toxicological data available to the Committee included results from the requested studies, as well as mutagenicity, reproduction, and teratogenicity data. Zeranol was shown to be a weak estrogen in long-term studies in mice, rats, dogs, and monkeys. Most of the changes noted occurred in mammary glands and organs of the reproductive tract. Zeranol did not cause changes in other reproductive parameters in rats, and was not teratogenic in mice or rats. Zeranol and its metabolites zearalanone and taleranol were not mutagenic in a number of tests in bacterial and mammalian systems. Zeranol (at an unspecified concentration) gave a positive result in the Rec-assay (Bacillus subtilis) and taleranol gave a positive result in the test with Chinese hamster ovary cells in the absence of activation, but a negative result with activation. In the carcinogenicity study performed in rats, dietary levels of zeranol up to 25 ppm (equivalent to 1.25 mg/kg b.w./day) had estrogenic but not carcinogenic effects. In the study performed in mice, zeranol had significant estrogenic effects in male mice in the highest dose group, receiving zeranol at 15 ppm in the diet (equivalent to 2.25 mg/kg b.w./day); these mice also showed a higher incidence of anterior lobe tumours of the pituitary gland than did mice in the negative control group. Such tumours rarely occur spontaneously in mice but are known to result from administration of estrogenic hormones. The positive control group receiving a diet containing 2.5 ppm estradiol-17ß showed a higher incidence of anterior lobe tumours of the pituitary than did either animals receiving zeranol or animals in the negative control group. Thus the Committee concluded that the carcinogenic effect of zeranol was associated with its estrogenic properties, and that the determination of a no-hormonal-effect level for tumours would permit an estimate of safe levels of exposure to be made. A no-hormonal-effect level could not be established in male cynomolgus monkeys since no estrogenic effects were observed even at the highest dose administered (5 mg/kg b.w./day). In intact female cynomolgus and rhesus macaque monkeys, 5 mg/kg b.w./day was established as a no-hormonal-effect level. In ovariectomized female cynomolgus monkeys the no-hormonal-effect level was 0.05 mg/kg b.w./day. The Committee concluded that this model could be relevant to the human population and, since the ovariectomized female cynomolgus monkey is highly sensitive to estrogenic substances, adopted a conservative approach by using this study as a basis for setting an ADI for human beings. EVALUATION Level causing no hormonal effect Monkey: 0.05 mg/kg b.w./day. Estimate of acceptable daily intake 0 - 0.5 µg/kg b.w. REFERENCES Albany Medical College (1980). A) Twenty-four hour acute toxicity in rats. B) Four-day subacute toxicity in rats. Unpublished report from Albany Medical College. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Bartholomew, R.M. & Ryan, D.S. (1980). Lack of mutagenicity of some phytoestrogens in the Salmonella/mammalian microsome assay. Mutat. Res., 78, 317-321. Brusick, D.J. & Myhr, B.C. (1986). Evaluation of taleronol in the mouse dominant lethal assay. Unpublished report No. 22203 from Hazelton Biotechnologies Co., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. CIC (1985). Maturation index in castrate cynomolgus monkeys receiving zeranol. Unpublished report from Coulston International Corp., Alamogordo, NM, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Cifone, M.A. (1982). Mutagenicity evaluation of zeranol in the mouse lymphoma forward mutation assay. Unpublished report No. 20989 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Cifone, M.A. (1983). Mutagenicity evaluation of zearalanone in the mouse lymphoma forward mutation assay. Unpublished report No. 20989 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Cifone, M.A. (1985). Mutagenicity evaluation of taleranol in the mouse lymphoma forward mutation assay. Unpublished report No. 20989 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Cimino, M.C. (1982). Mutagenicity evaluation of zeranol in the mouse bone marrow cytogenic assay. Unpublished report from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Cimino, M.C. (1983). Mutagenicity evaluation of zearalanone in the mouse bone marrow cytogenic assay. Unpublished report No. 22202 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Davis, G.I., McLachlan, J.A., & Lucier, G.W. (1977). Fetotoxicity and teratogenicity of zeranol in mice. Tox. Appl. Pharm., 41, 138-139. Everett, D.J., Perry, C.J., & Jones, M. (1983). Zeranol, 13 week toxicity study in rats (oral administration by diet). Unpublished report No. 430336 from Inveresk Research International, Musselburgh, Scotland. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Everett, D.J. & Perry, C.J. (1984). P-1496 reproductive performance study in rats (oral administration by diet). Unpublished report No. 430603 from Inveresk Research International, Musselburgh, Scotland. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Everett, D.J., Perry, C.J., & Houroyd, P. (1987a). P-1496 104 week carcinogenicity study in mice (dietary administration). Unpublished report No. 3624 from Inveresk Research International, Musselburgh, Scotland. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Everett, D.J., Perry, C.J., & Aitken, R. (1987b). P-1496 104 week carcinogenicity study in rats (dietary administration). Unpublished report No. 3630 from Inveresk Research International, Musselburgh, Scotland. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Everett, D.J., Perry, C.J., Scott, K.A., Martin, B.W., & Terry, M.K. (1987c). Estrogenic potencies of resorcyclic acid lactones and 17-ß-estradiol in female rats. J. Tox. and Envir. Health, 20, 435. Gardner, W.U. (1941). The effect of estrogen on the incidence of mammary and pituitary tumors in hybrid mice. Cancer Research, 1, 345-358. Gardner, W.U. (1948). Hormonal imbalance in tumorigenesis. Cancer Research, 8, 397-411. Hess, D.L. (1986). Determination of the hormonal no-effect dose level for zeranol in the female rhesus macaque. Unpublished report from Oregon Regional Primate Research Center, Beaverton, OR, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Hogan, G.K. (1981a). A seven-year oral toxicity study of P-1496 in female beagle dogs. Unpublished report No. 69-458 from Bio/dynamics Inc., East Millstone, NJ, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Hogan, G.K. (1981b). A ten-year oral toxicity study of P-1496 in female rhesus monkeys. Unpublished report No. 69-457 from Bio/dynamics Inc., East Millstone, NJ, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Huis In't Veld, L.G. & Kroes, R. (1974). Report of the National Institute of Public Health of the The Netherlands, 89-74 Endo interim report. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Ingerowski, G.H., Scheutwinkel-Retch, M., & Stan, H.-J. (1981). Mutagenicity studies on veterinary anabolic drugs with the Salmonella/microsome test. Mutat. Research, 91, 93-98. IMC (1980a). Preclinical evaluation and three-generation reproduction and teratology study in rats. Unpublished report from International Minerals & Chemical Corp., Terre Haute, IN, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. IMC (1980b). Acute toxicity. Unpublished report from International Minerals & Chemical Corp., Terre Haute, IN, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. IMC (1980c). Six-week oral range finding study in the rat. Unpublished report from International Minerals & Chemical Corp., Terre Haute, IN, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. IMC (1980d). Subacute toxicity. Two-week subacute toxicity in the rat. Unpublished report from International Minerals & Chemical Corp., Terre Haute, IN, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Ivett, J.L. (1985a). Clastogenic evaluation of taleranol in the mouse bone marrow cytogenic assay. Unpublished report No. 22202 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Ivett, J.L. (1985b). Clastogenic evaluation of taleranol in an in vitro cytogenic assay measuring chromosomal aberration frequencies in Chinese hamster ovary (CHO) cells. Unpublished report No. 20990 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Jagannath, D.R. (1982a). Mutagenicity evaluation of zeranol in the Ames Salmonella/microsome plate test. Unpublished report No. 20988 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Jagannath, D.R. (1982b). Mutagenicity evaluation of zearalanone in the Ames Salmonella/microsome plate test. Unpublished report No. 20988 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by IMC Corp., Terre Haute, IN, USA. Jagannath, D.R. (1983). Mutagenicity evaluation of taleranol standard in the Ames Salmonella/microsome plate test. Unpublished report No. 20988 from Litton Bionetics, Inc., Kensington, MD, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Perry, C.J. & Everett, D.J. (1984). P-1496 8-week toxicity study in mice, with dietary administration. Unpublished report no. 3168 from Inveresk Research International, Musselburgh, Scotland. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Scheutwinkel, M., Hude, W. v.d., & Basler, A. (1986). Studies on the genotoxicity of the anabolic drugs trenbolone and zeranol. Arch. Toxicology, 59, 4-6. Singh, A.R. & Griffin, T.B. (1984). To determine oral dose of zeranol for no-hormonal effect in non-human primates. Part IV. Supplement. Unpublished report No. 820111 from Coulston International Corp., Alamogordo, NM, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Singh, A.R., Griffin, T.B., & Coulston, F. (1984a). To determine oral dose of zeranol for no-hormonal effect in non-human primates. Part I. Studies on ovariectomized cynomolgus monkeys. Unpublished report No. 82011 from Coulston International Corp., Alamogordo, NM, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Singh, A.R., Griffin, T.B., & Coulston, F. (1984b). To determine oral dose of zeranol for no-hormonal effect in non-human primates. Part II. Studies in male cynomolgus monkeys. Unpublished report No. 82011 from Coulston International Corp., Alamogordo, NM, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Singh, A.R., Griffin, T.B., & Coulston, F. (1984c). To determine oral dose of zeranol for no-hormonal effect in non-human primates. Part III. Studies in intact cynomolgus monkeys. Unpublished report No. 820111 from Coulston International Corp., Alamogordo, NM, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Wazeter, X.F. & Goldenthal, E.J. (1976). Three-generation reproduction and teratology study in rats. Unpublished study No. 267-010 from International Research and Development Corp., Mattawan, MI, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Williams, R.D. (1982). Safety information on compound P-1496, the active material in RALGRO(R). Submitted to WHO by International Minerals & Chemical Ltd., London, England. Williams, G.M. (1983). The hepatocyte primary culture/DNA repair assay on compound P-1496 using rat hepatocytes in culture. Unpublished report from American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, NY, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Williams, G.M. (1984). DNA damage and repair tests for the detection of genotoxic material. Food Additives and Contaminants, 1, 173-178. Williams, G.M. (1985a). The hepatocyte primary culture/DNA repair assay on zealalanone using rat hepatocytes in culture. Unpublished report from American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, NY, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Williams, G.M. (1985b). The hepatocyte primary culture/DNA repair assay on compound taleranol using rat hepatocytes in culture. Unpublished report No. PLR-821 from American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, NY, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England. Woodard, G. (1968). P-1496 safety evaluation by dietary administration to rats for 105 weeks. Unpublished report from Woodard Research Corp., Herndon, VA, USA. Submitted to WHO by International Minerals & Chemical Ltd., London, England.
See Also: Toxicological Abbreviations ZERANOL (JECFA Evaluation)